Skip to main content
. 2020 Oct 13;21:265. doi: 10.1186/s12931-020-01513-x

Fig. 2.

Fig. 2

Study design. *For participants who cannot visit the study site at week 28 owing to the COVID-19 pandemic, treatment can be extended to up to 52 weeks until they are able to visit the study site. Q4W, every 4 weeks. SC, subcutaneous